¤E¤Q¤C¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¤ßŦ¬ì

(D) 1.¯f¤H62·³¡A¨k©Ê¡A¦b6¤ë8¤é²M±á6®É¬ðµM¦³ÄY¼F¯Ý¯kµo¥Í¡A¥H­P¿ô¨Ó°_§É¡AÀH§Yµo¥Í«_¦½¡Bäú ¤ß¡B¹Ã¦R¤Î¸¡µh¡A¤D«æ©¹Âå°|¨Dªv¡C¯f¤H¦³°ª¦åÀ£¤Î³h¦å¯f¥v¡C²z¾ÇÀˬdÅã¥Ü«æ¯f­±®e¡A¦åÀ£250/100 mmHg¡A¤ß¸õ67/min¡A¤ßªÍ¨ÃµL¥ô¦ó²§±`¡A¦ý¸¡³¡¸zį°ÊÁn´î¤Ö¡A¦Ó¥B¦³¸¡¦ÙÃø¸I¤§ª¬¡A¥k¸}½ïdorsalis pedis¯ß°Ê®ø¥¢¡C¯Ý³¡X¥ú¤Î¤ß¹q¹Ï¦p¥Ü¡C¨ä¥L¼v¹³¦p¹Ï ¡C¦å²GÀˬd¡AAST 29 U/L¡FCK 102.0 U/L¡FCK-MB 22.4 U/L¡FTroponin I <0.04 £gg/L¡FAmylase 80 U/L¡FLipase 32 U/L¡FNa 3.3 mEq/L¡FK 3.3 mEq/L¡FD-dimer 12-24 £gg/ml ¡FBUN 53.6 mg/dl¡FCreatinine 2.6mg/dl¡C¯f¤HªA¥ÎClondine (0.075 mg) 6#bid¡F Doxazosin (1 mg) 2#hs¡FAmlodipine (5 mg) 1#bid¡FTrichlorthiazide (2 mg) 1#qd¡FMinoxidil (10 mg)2#bid¡FValsartan 1#qd¡F Metoprolol (100 mg) 1/2#qd¡C½Ð°Ý¥»¯f¤H³Ì¥i¯àªº¶EÂ_¬O¡G
A.«æ©Ê¤ß¦Ù±ð¶ë
B.ªÍ°Ê¯ß®ê¶ë¦X¨ÖªÍ°Ê¯ß°ª¦åÀ£
C.«æ©Ê¤ß°IºÜ¯g
D.¥D°Ê¯ß­éÂ÷
E.´c©Ê°ª¦åÀ£
 
(A) 2.¦³Ãö«æ©Ê¥D°Ê¯ß¯g­Ô¸s(Acute aortic syndrome)ªºÁ{§É»¡ªk¦³¡G (1)¸¡³¡¥D°Ê¯ß½F(Aorticaneurysm)ª½®| > 5cmªÌ¸û <5cmªÌµo¥Í¥D°Ê¯ß¯}µõªº¾÷·|¼W¥[20­¿(2)¥D°Ê¯ß½F¦ñ¦³°ª¦åÀ£®É±o³æ¥Îdiazoxide©Îhydralazineª`®gªvÀø (3)¤W¤É¥D°Ê¯ß­éÂ÷(Dissection)¡BºÞ¤º¦å¶ô(Intramuralhematoma)¤Î¶i®i¤¤ªº¤U­°¥D°Ê¯ß­éÂ÷À³¥H¥~¬ì¤â³N¬°¥D (4)µo¥Í¤W¤É¥D°Ê¯ß½F¯f¦]¥H°Ê¯ßµ°ª¬µw¤Æ¬°¦h¡A¦Ó¤U­°¥D°Ê¯ß«h¥HCystic medialnecrosis¬°¦h¤U¦C¦óªÌÁ{§É»¡ªk¬O¥¿½Tªº¡H
A.1+3
B.2+4
C.1+2
D.1+4
E.3+4
 
(B) 3.±q¯f¦]¦Ó¨¥¡A¤U¦C¦óºØ­ì¦]»P¹¬´Uä¯U¯¶ªº­P¯f¾÷ÂàµLÃö¡H
A.­·Àã¼ö
B.¤ß¤º½¤ª¢
C.¥ý¤Ñ·î§Î²§±`
D.¹¬´UäÀô­««×¶t¤Æ(Severe mitral annular calcification)
E.¬õ´³©Ê¯T½H¯g(SLE)
 
(E) 4.¤U¦C¦óºØÅ¥¶Eªº²Õ¦X¬O¥¿½Tªº¡G(1)Mitral stenosis ~ Austin-Flint murmur(2)Rheumatic fever ~ Carey-Coombs murmur(3)Aortic regurgitation ~ Gallavardin murmur(4)Mitral valve prolapse ~ Mid-systolic click & late systolic murmur
A.1+2
B.1+3
C.1+4
D.2+3
E.2+4
 
(E) 5. 29·³¤k©Ê¡A¥D¶Dªñ¦~¨Ó¦³¶i®i©ÊÂù¸}¤ô¸~¡A¥þ¨­­Â«å¡A¦P®É¦ñ¦³¹B°Ê©Ê©I§l§xÃø¤Î¸¡³¡¸~µÈ¡C¯f¤H¦b¤Q¦h¦~«e¦³¬õ´³©Ê¯T½H¡A¤]¦]¦¹¥|³B¨DÂå¡A»~«H¯óÃÄ¡A²×­PµÇ¯f¥½´Á¤§§¿¬r¡A¬I¦æ¦å²G³zªRªvÀø¡C©ó¤µ¦~4¤ë24¤é­u¤¤°ê±µ¨üµÇŦ²¾´Ó¡A¤£·N³N«á¦³½Ñ¦h¨Öµo¯g¡A¦p§¿¸ô·P¬Vµ¥¡A¦^°ê¤@ª½¦bªù¶EªvÀø¡Cªñ¦h¤ë¨Ó¡A¤W­z¯gª¬³vº¥¥[¼@¡A¤D¦í°|¶EÀø¡C²z¾ÇÀˬd:¦åÀ£96/55 mmHg;¤ß¸õ75/min³W«h¡F©I§l 18/min¡A©|ÄÝ¥­Ã­¡A¯f¤H§e²{ºC¯fª¬¡AÁy¦â»a¥Õ¡AÀVÀR¯ß«ã±i¡A¦³Kussmaul's sign¡A¯Ý³¡¥¼¦³Àã¿BÁn¡A¤ßŦ¤§point of maximal impulse (PMI)¤£²M¡AS1¤ÎS2©|ÄÝ¥¿±`¡A¥¼¦³¤ßÂø­µ¡A¸¡³¡¥¼¦³¨xµÊ¥iIJª¾¡AÂù¤UªÏ¦³¤ô¸~¡C¹êÅç«Ç¦³WBC¡A5520¡FRBC¡A3,010,000¡FHb¡A10.1 g/dl¡ABUN¡A40 mg/dl¡FCreatinine¡A1.79mg/dl¡A¾l¬Ò¥¿±`¡C¨ä¥L¯Ý³¡X¥ú¡B¤ß¹q¹Ï¤Î¤ßŦ¹q¸£Â_¼h ¦p¹Ï¥Ü¡C½Ð°Ý¥»¯f¤H³Ì¥i¯àªº¶EÂ_¬O¡G
A.¥ª¤ßŦ°IºÜ
B.¥k¤ßŦ°IºÜ
C.«a¤ß¯g
D.¤ß¦Ù¯fÅÜ
E.¯¶ÁY©Ê¤ß¥]½¤ª¢ (constrictive pericarditis)
 
(D) 6.¦³Ãö°ª¦åÀ£ªº­z»¡¡A¦óªÌ¬O¤£¥¿½Tªº¡G
A.¥H¦åÀ£¶q´ú½×Â_°ª¦åÀ£¬O¿ù»~ªº¡A¦]ÀHµÛ¦åÀ£ªº¼W¥[¡A¨ä¹ï¦åºÞ¤§¶Ë®`¬O³vº¥¤Î«ùÄò¥[­«
B.°ª¤ßÁY¦åÀ£(Systolic BP)¤ñ°ª¤ßµÎ¦åÀ£(Diastolic BP)¹ï¦åºÞ¾À¶Ë®`§ó¤j
C.ÃĪ«ªvÀø°ª¦åÀ£¤£¯à©¿µø¨ä¥L¦MÀI¦]¯À¡A§_«h¦åÀ£¤£©ö±±¨î
D.¥Ø«eÃĪ«µo¹F¡A¦b§Ú°êÁ{§ÉªvÀø°ª¦åÀ£¤w¦³ªñ¥bªº°ª¦åÀ£¯f¤H¤w¹F¨ì±±¨î¥Ø¼Ð
E.·sªñ¦³¼Ú¬w°ê®aªvÀø«ü¤Þ¥D±i¡A±N£]-«¬¥æ·P¯«¸gªýÂ_¾¯¤Î£\-«¬¥æ·P¯«¸gªýÂ_¾¯­ç°£¦b²Ä¤@½u°ª¦åÀ£ªvÀøªºÃĪ«¤§¥~
 
(E) 7.¤U¦C¦³Ãö¤ßŦ°IºÜ­P¯f¾÷Â઺½Ñ¦h»¡ªk¡A¦óªÌ¬O¤£¥¿½T¡G
A.¯Ê¦å©Ê«a¤ß¯f³y¦¨ªº¤ß¦Ù¶Ë®`¥H¥ª¤ß«Ç¬°³Ì
B.¤ß¦Ù±`¥Hneurohormonal activation¨Ó¶i¦æcardiac remodeling¡A±q¦Ó§ïÅܤßŦµÄ«Ç¤j¤p¤Î¦å¦æ¤O¾Ç¶Ê­¢(stress)ÅܤơA¤]¦]¦¹´c¤Æ¤ßŦ¯gª¬
C.¦]À³¤ß°IºÜ·|¦³µÇ¯À-ª@À£¿E¯À¨t²Î(renin-angiotensin system)±Ò°Ê¡A¦Ó¦³µÇ¤§¤ô¤À¯d¸m¤Î¥½±é¦åºÞ¦¬ÁY§@¥Î¡A±q¦Ó²H¤Ænatriuretic peptide¤§«ú§Ü¦åºÞ¦¬ÁY¡A´c¤Æ¤ßŦ¥\¯à
D.¤ß¦Ù¦¬ÁY¤O°I°h±`­nÂǧU¦åºÞ¤º¦å¶qÂX±i¡A¥Hºû«ù¥­¿Å©Êªº«aª¬¦å¬y´`Àô¡A¤@¥¹¥¢¿Å¯gª¬´c¤Æ§ó¬Æ
E.±q­P¯f¾÷Âà¡A¤ß°IºÜ¬O«ö§Ç¶i®i¡A±q¤ßŦ¶Ë®`¡A¦A¦¸neurohormonal activation¡B¤ô¤À¶J¯d¤Î¦åºÞ¦¬ÁY¦Ó«á¤ßÁY¤O°h¤Æ¡A²×­P¦º¤`¡A¤£·|¤¤³~¾÷ÂणÄò¦Ó¬ðµM¦º¤`
 
(E) 8.¦³Ãö¤ß°IºÜªºÃĪ«ªvÀø¤è¦¡¡A¤U¦C¦óªÌ¤£ºÉ¾A¤Á¡G
A.¤ò¦a¶À¥i§í¤î¶u¹[Â÷¤l ATPase¦Ó¥[±j¤ßÁY¤O¡A¦ý¥ç¥i¼vÅT¥æ·P¯«¸g¬y¶Ç¿é¡A¦]¦¹±j¤ß§@¥Î¸û§C
B.£]¥æ·P¯«¸g§í¨î¾¯¥i½Õ©Mneurohormonal activation¬ÛÃö¤§¤ß¦Ù²Ó­M¦º¤`¡B¯Ê®ñ¤ÎªÎ«p¤ß¦Ùµ¥ÅܤÆ
C.ª@À£¯ÀÂà¤ÆúC(Angiotensin-converting enzyme)§í¨î¾¯¥i§ïµ½cardiac remodeling¡AÀ³¸Ó­n¨Ï¥Î
D.§Q§¿¾¯¥i§ïµ½¶u¤Î¤ô¤À¤§¶J¯d¡A ¬O¤ß°IºÜ¤£¥i©Î¯Ê¤§ÃĪ«ªvÀø
E.Á{§É¸gÅçÅã¥Ü£]¥æ·P¯«¸g§í¨î¾¯ªº¨Ï¥Î¡AÀ³¦bª@À£¯ÀÂà¤ÆúC§í¨î¾¯¨Ï¥Î«e¸û§´
 
(B) 9.¦³Ãö«aª¬°Ê¯ßµ°ª¬µw¤Æ©Ò¾É­P¤ß¦Ù¯Ê®ñ¤§¯f²z¥Í²zÅܤơA¤U¦C¦óªÌ»¡ªk¬O¿ù»~ªº¡G
A.¾É­P¤ßµ±¯k¬O¦]adenosine¤Îbradykinin¨ë¿E¤ß¦Ù¤§chemosensitive ¤Îmechanosensitive receptors¦Ó°_
B.¤ß¦Ù¯Ê®ñ¤§cascade«ö§Ç¥ý«á¡A¥ý¦³¤ß¦Ù¯Ê®ñ¤§¤ß¹q¹ÏÅܤơAÀH«á¦³¤ßµÎ¥¢¯à¡B¤ßÁY¥¢¯à¤Î¤ßµ±¯k·µ«á
C.¨M©w¤ß¦Ù¯Ê®ñ¤§¦]¤l«ö¨ä¼vÅT«×¥H¤ß¸õ¦¸¼Æ³Ì­«¡A¨ä¦¸¨Ì§Ç¬°¤ß¾À±i¤O(afterload)¡B¤ß¦¬ÁY¤O¤Î¤ßµÎ®e¶q(preload)
D.¤ß¦Ù¯Ê®ñ®É«a¯ß¦å¬y¤¤®ñ®ð±Ä¶q¼W¥[¡A¦ý¤´¥H«a¯ß¦å¬y¶q¼W¥[5¦Ü6­¿¬°³Ì½Õ¾A¤è¦¡¡A¥H¸Ñ°£¯Ê®ñ
E.¤@¯ë«a¯ßª½®|¯U¯¶¤j©ó50%³Ì©ö¥X²{¯Ê®ñ
 
(B) 10. ¯f¤H¸â§dXX¡A86·³¤k©Ê¡A¤µ¦~¦~ªì°_®É¦³¹B°Ê©Ê¤ßµ±¯k¡A¨ä¯gª¬ªA¥Î¦Þ¤U¨Èµv»Ä¥Ìªo¤ù¥i½w¸Ñ¡A°ß¨C¤Ñ»Ý¥Î2¦Ü4²É¡A¤éÁÍÀWÁc¡C¦Ó¥Bªñ¤ë¨Ó±¡ªp´c¤Æ¡A´X¥G¤£´±µy¨Æ¹B°Ê¡A²×¤é®a©~¡AµLªk¥Xªù¬¡°Ê¡C¯f¤H¦³°ª¦åÀ£¡B¿}§¿¯f¤Î°ª¯×¦å¤Q¦h¦~¯f¥v¡A§¡±µ¨üÃĪ«ªvÀø¤¤¡A¯f¤HªA¥ÎASA¡A50 mg/day¡FClopidogrel¡A75 mg qd¡FValsartan¡A80 mg qd¡FCarvedilol¡A6.25 mg qd¡FAmlodipine¡A5 mg qd¡FAtorvastatin¡A10 mg hs¡FPioglitazone¡A30 mg qd¡FGliclazide¡A30 mg bid/ac¡FMetformin¡A500 mgbid/pcµ¥ªvÀø¡C²z¾ÇÀˬd¡G¦åÀ£¡A114/49 mmHg¡F¤ß¸õ¡A68/min¡F¨­°ª¡A151.6 cm¡FÅé­«¡A48 kg¡F¤ßŦ¤j¤p¥¿±`¨ÃµL¨ä¥L²§±`¤ß­µ¡A¨ä¥L¦U¾¹©x¨t²Î©|µL²§±`©Ò¨£¡C¨ä¦å²MCK¡A48 U/L(normal¡A50 -294U/L)¡FTroponin I.<0.4 £gg/L¡F¦å¿}¡A132 mg/dl¡FÁx©T¾J¡A168 mg/dl¡FLDL-c 84 mg/dl¡FHDL-c¡A36mg/dl¡C¨ä¯Ý³¡X¥ú¤Î¤ß¹q¹Ï¦p¹Ï ¡C¨Ì¾ÚACC/AHA2007«ü¤Þ¡A¥»¯f¤HÀ³¥H¦ó¶µ³B¸m¬°³Ì«ê·í¡G
A.¦~¨Æ°ª¨ÃµL¤ß¦Ù¶ËÅÜ¡A¥H«O¦uªvÀø¬°©y
B.À³¿n·¥±q¨Æ¸g¥Ö«a¯ßªý¤¶©Î¥~¬ìªvÀø¤~¦X¥G«ü¤Þ
C.¥i¥HÂIºwÀR¯ßª`®gNitroglycerin
D.¥[±j¿}§¿¯f¤Î°ª¯×¦åÃĪ«ªvÀø
E.¥i¦^®a¥ð¾i
 
(B) 11. QRS§Cªi(low voltage of QRScomplex)¥i¨£©ó¦hºØ¯fªp¡G(1)ªÎ­D¯g¡A(2)°ª¦åÀ£¡A(3)®ð¯Ý¡A(4)¥Òª¬¸¢¾÷¯à¤®¶i¡A(5)¤ß¦Ù¯f¡C½Ð¤U¦C¦óÃþ¯fªp²Õ¦X¤~¦³QRS§Cªi±¡ªp?
A.(1) + (2) + (3)
B.(1) + (3) + (5)
C.(2) + (4)
D.(2) + (5)
E.(4) + (5)
 
(E) 12.¤@¦ì48·³¤k©Ê¦]¤ß±ª¡A©I§l§xÃø¦Ü«æ¶E«Ç¨D¶E¡A¤ß¹q¹Ï¦p¤U¡A¥H¤U±Ô­z¦óªÌ³Ì¾A·í¡G
A.¤ß¹q¹ÏÅã¥ÜÄY­«ªº¤ß«ÇÀW¯ß(Ventricular tachycardia)¡AÀ³¥ß§Yµ¹¤©ÀR¯ßª`®glidocaine¡C
B.­Y¦¹®É¥Í©R¼x­Ô©|ºÙí©w¡A¥i¥H¦Ò¼{¥ý¥HÀR¯ßª`®gverapamilªvÀø¡C
C.­Y¦¹®É±wªÌ¥Í©R¼x­Ô¤£Ã­©w¡A¥i¥H¤£¦P¨B¾ã¬y¥hŸ¹qÀ»¨ÓªvÀø
D.¤j³¡¤À¦³¦¹ºØ¤ß«ß¤£¾ãªº±wªÌ¡A¦h¨ã¦³¼ç¦b©Êªº¤ßŦµ²ºc©Ê¯e¯f¡C
E.³o­Ó¯f¤HÀ³¦s¦b¦³¥k°¼«á¤¤»J(posteroseptal)¤è¦Vªº©Ð«Çaccessory pathway¡C
 
(B) 13.¤@¦ì55·³¨k©Ê¡A¥H©¹¶Èª¾¦³°ª¦åÀ£¯f¥v¡A¦b°·Àˮɤ߹q¹Ïªí²{¦p¤U¡A¥H¤U±Ô­z¦óªÌ³Ì¤£¾A·í¡G
A.À³¦Ò¼{À°¯f¤HÀˬd¥Òª¬¸¢¥\¯à¡C
B.¦b¦Ò¼{´À¯f¤H¹ê¦æ¹q®ð¥hŸ³N(electrical cardioversion)«e¡A¶·¥ýµ¹¤©§Ü¾®¦å¾¯3¶g¡A¥hŸ¦¨¥\¦¨¬°Äu©Ê¤ß«ß(sinus rhythm)«á¡A´N¥i¥H°±ÃÄ¡C
C.­Y¯f¤H¨S¦³«a¤ß¯gµ¥¼ç¦bªºµ²ºc©Ê¤ßŦ¯f¡A¥i¥H¦Ò¼{µ¹¤©¤fªAªºpropafenone§@pharmacological cardioversion¡C
D.¥Î©óªvÀøªºÃĪ«¤§¤@¡Aamiodarone¡A¥i¯à¦b1©P¤º´N¥X²{ªÍ³¡¬r©Ê¡C
E.®Ú¾ÚAFFIRM¬ã¨sµ²ªG¡Aªø´Á¦Ó¨¥rhythm control (±±«ß)ªºµ²ªG¨Ã¥¼Àu©órate control (±±³t)¡C
 
(A) 14.µh¤§°_©lµo§@«¬ºA(mode of onset)¦bŲ§O¶EÂ_¤W·¥¬°­«­n¡A¤U¦C¥i¯à¥H¯Ýµhªí²{¤§«æ¯g¤¤¡A¨äµh¤§°_©lµo§@«¬ºA¬°¶W«æ©Ê(abrupt or dramatic onset) - §Y¨äµh¬ðµMµo¥Í¡A¨äµ{«×Àþ¶¡©Î¨³³t¹F¨ì·¥ÂI(´¸¤ÑÅRÆE¦¡) ªÌ¡A¦óªÌ¬°¨Ò¥~¡H
A.«æ©Ê¤ß¦Ù±ð¶ë
B.¥D°Ê¯ß­éÂ÷¯g
C.­¹¹D¯}µõ
D.®ð¯Ý(pneumothorax)
E.¥H¤W¬Ò¥¿½T
 
(C) 15.¤W©I§l¹Dªý¤O«æ¼@¼W¥[(¦p©Þ°£®ðºÞ¤ººÞ«á¤§³ïÄVµjÅË¡B«æ©Ê·|¹½³n°©epiglottisµoª¢µ¥) ©Î¦]¤j¶q¦Ø½¤¿n¤ô¤Þ¬y¹L§Ö¤Þ°_¤§ªÍ¤ô¸~¡A¨ä¾÷¨î¬°¦ó¡H
A.ªÍ³¡ÀR¯ß¡B·L¦åºÞÀR¤ôÀ£(hydrostatic pressure)¤Wª@
B.ªÍªw¤Î·L¦åºÞ¤º¥Ö³q³z©Ê(permeability)¼W¥[
C.¶¡½èÀR¤ôÀ£(perivascular hydrostatic pressure)¤U­°
D.½¦Å麯³zÀ£(colloid oncotic pressure)¤U­°
E.¥H¤W¬Ò«D
 
(E) 16.¤U¦C§Ü¦å¤pªO¾¯¤Î§Ü¾®¦å¾¯¤§§@¥Î¾÷Âà¡A­þ¤@­ÓÃĪ«»P§@¥Î¾÷Âध°t¹ï¬°»~?
A.Fondaparinux -- Xa inhibitor
B.Ticlopidine¡Bclopidogrel -- ADP¨ü®e¾¹ (receptor) ªýÂ_¾¯
C.Abciximab¡Btirofiban¡Beptifibatide -- glycoprotein IIb/IIIa¨ü®e¾¹¤§ªýÂ_¾¯¡AªýÂ_¦å¤pªO»Pfibrinogen¤§µ²¦X
D.Bivalirudin -- ª½±µ¤§§Üthrombin¾¯ (direct thrombin inhibitor)
E.¥H¤WªºÃĪ«»P§@¥Î¾÷Âৡ¬°¥¿½T´y­z
 
(E) 17.°ª¦åÀ£¯f¤H¡A¤U¦C¦óºØ±¡ªp¯f¥vÀ³ÃhºÃµÇ°Ê¯ß¯U¯¶¾É­P¤§µÇ¦åºÞ©Ê°ª¦åÀ£(renovascular hypertension)?
A.³Ìªñµo¥Í¤§°ª¦åÀ£ ¡A¤×¨ä¯f¤H¦~ÄÖ < 30©Î > 50·³
B.Accelerated hypertension (¦åÀ£¸`¸`ª@°ª) ©Î resistant hypertension (¹x§Ü©Ê°ª¦åÀ£) (¦hºØÃĪ«°ª¦åÀ£©Î¦åÀ£³Ìªñ¹ïªA¥Î¤§ÃĪ«µo¥Í§ÜÃÄ©Ê)
C.¨Ï¥ÎACEI (Angiotensin Converting Enzyme Inhibitor)©ÎARB (Angiotensin Receptor Blocker) «áµÇ¥\¯à«æÁØ´c¤Æ
D.Acute pulmonary edema(«æ©ÊªÍ¤ô¸~)
E.¥H¤W¬Ò¥¿½T
 
(A) 18. ¤@¦W60·³¥ªºJ¤l(left-handed)¨k©Ê¡A ³Ìªñ¦b¥´ºô²y®É¥ª¤â®e©öµL¤O¡Bµo³Â¬Æ¦Üµo¥ÍÀY·w¡B©ü³Ö¦Ó¨D¶E¡C²z¾ÇÀˬdµo²{¯f¤H¥ª¥kÂù¤â¦åÀ£¤À§O¬°134/72¡B110/66 mmHg¡A¨â¤â¸}·Å·xµLµoÖæ²{¶H¡A¥ª¾ø°©°Ê¯ß·i¤ñ¥k°¼µy®z¡AÀVÀR¯ßÀ£¥¿±`¡AÀV°Ê¯ß¯ß·i¥¿±`¡A¥ªÂê°©¤WºÛ¦³¦¬ÁY´ÁÂø­µ©µ¦ù¦ÜµÎ±i´Á¡A¤ßŦ¤j¤p¥¿±`µLÂø­µ¡A¥½±é°Ê¯ß¯ß·i¥]¬AªÑ°Ê¯ß±j«×¥¿±`¡C¥H¤U±Ô­z¤§²Õ¦X¦óªÌ¤£¥¿½T?1.¯f¤H¥ªÂê°©°Ê¯ß¦³ÄY­«¯U¯¶¾É­P subclavian steal syndrome2.¯f¤H¦³¥ª¤WªÏ ¶¡·²©Ê¶_¦æ(intermittent claudication)3.ÁöµM¥ªÂê°©°Ê¯ß¯U¯¶¦ý¦³¨}¦n¤§°¼°Æ´`Àô(collateral circulation)¡A¦]¦¹¯f¤H¥­®É¥ª¤â·Å·xµLµoÖæ²{¶H4.¤WªÏ°õ¦æelevation-dependency test(¤WÁ|¡B¤U««Àˬd)À³¬°²§±`5. ¯f¤H¥´ºô²y®É¦]¦åÀ£¤U­°µo¥ÍÀY·w¡B©ü³Ö
A. 5
B. 2 + 5
C. 2 + 3 + 4
D.1 + 2 + 4 + 5
E.¥H¤W¬Ò¥¿½T
 
(B) 19.¤ß¦Ù®ñ®ð»Ý¨D¶q¨ú¨M©ó ¤ß³t²v¡B¤ß«Ç¾À±i¤O(wall tension)¤Î¤ß¦Ù¦¬ÁY¤O (contractility)¡C¦Ó¨Ì ©Ô´¶©Ô´µ©w«ß(Laplace law)¡A ¤ß«Ç¾À±i¤O»P¤ß«ÇÀ£¤O¤Î¤ß«Ç¤j¤p§e¥¿¬ÛÃö¡C¤U¦C±¡ªp¦óªÌ¤£·|¼W¥[¤ß¦Ù®ñ®ð»Ý¨D¶q?
A.¤ß«Ç°IºÜ ¨Ï¥Î±j¤ß¾¯¡A¦pdigoxin, dopamine
B.¨Ï¥Î ¤A«¬¥æ·P¯«¸gªýÂ_¾¯(beta-blocker)©Îµv»ÄÆQ (nitrates)
C.¦åÀ£¤É°ª
D.¤ß«ÇÂX¤j
E.¤ß³t²v¼W¥[
 
(C) 20.¤ß¦åºÞ¨t²Î²z¾ÇÀˬdÀ³µø¶E¡BIJ¶E»PÅ¥¶E¦P¨B°õ¦æ¡A¨Ã¨Ì»Ý­n§ïÅܨü¶E¤HÅé¦ì«º¶Õ¡C¥H¤U¦CÁ|¤§±Ô­z¦óªÌ¤£¥¿½T?1. ¦b²Ä¤G¦Ø¶¡¥k¯Ý°©½t°Ï(¥D°Ê¯ßä°Ï)Å¥¶E¡A¦bÀV°Ê¯ß¯ß·i©Î¤ß¦y³Õ°Ê«eÅ¥ ¨£¤§¤ß­µ¬°²Ä¤@¤ß­µ¡A¦b¥¿±`¤H¤ñ¸û»´¬X©Î¤£©úÅã¡A¦pªG²Ä¤@¤ß­µ©úÅã©Î¤jÁnªí¥Ü²Ä¤@¤ß­µ¼W±j¡AÀ³¦Ò¼{¤G¦yä¯U¯¶©ÎPR¶¡¶ZÁYµu(short PR interval)2. ¦b²Ä¤G¦Ø¶¡¥ª¯Ý°©½t°ÏÅ¥¶E¡A¦bÀV°Ê¯ß¯ß·i©Î¤ß¦y³Õ°Ê«áÅ¥¨£¤§²Ä¤G¤ß­µ¡A¦b¥¿±`¤H©I®ð®É¬°³æ­µ¡A§l®ð®É¬°Âù­µ(A2¦b«e¡BP2¦b«á¡A¦¹¬°²Ä¤G¤ß­µ¤§¥¿±`¤Àµõ(normal splitting)3. ¦pªG²Ä¤G¤ß­µ©I®ð§l®ð¬Ò§eÂù­µ¡AÀ³¦Ò¼{¥ª§ô¶Ç¾Éªýº¢(left bundle branch block)4.¥¿±`¨ü¶E¤H±Ä§¤«º®É¦bÂê°©¤W½tÀV³¡Æ[¹î¤£¨ì¤ºÀVÀR¯ßªi°Ê¡A¦¹¦]Âê°©¤W½t³B¶Z¯Ý°©Åé»P¯Ý°©¬`¥æ¬É(manubro-sternal junction¡A§Y¸ô©ö¤h¨¤Louis Angle)««ª½°ª«×¬ù6-8 ¤½¤À¡A¦Ó¥¿±`ÀR¯ßÀ£¤p©ó10¤½¤À¤ô¬W¡C¦]¦¹Æ[¹îÀVÀR¯ßÀ³¦b¾A·í¨¤«×¤§¥õ½ö«º¬°¤§¡AÀR¯ßÀ£·¥°ªªÌ¬Æ¦Ü±Ä§¤«º5. ªý¶ë©ÊªÎ«p©Ê¤ß¦Ù¯g¤§¦¬ÁY´ÁÂø­µ¦b¯¸¥ß®ÉÅܤp¡AÃÛ¤U®ÉÅܤj
A. 3
B.1 + 4
C.3 + 5
D.2 + 3 + 5
E.1 + 3 + 4 + 5
 
(C) 21.¤U¦C¯f¤H§@¤ú¬ìªvÀø®É¶·µ¹§Ü¥Í¯À°µ·P¬V©Ê¤ß¤º½¤ª¢¤§¹w¨¾¡A¦ý¥H¦óªÌ°£¥~?
A.¥D°Ê¯ßä¯U¯¶
B.´«¹L¤H¤u佤¤§¯f¤H
C.¤w©¹§@¹L«aª¬°Ê¯ßëйD¤â³N
D.¤G¦yä²æ««¨Ö¦³¥þ¦¬ÁY´ÁÂø­µ
E.¤w©¹µo¥Í¹L¤ß½¤ª¢
 
(B) 22.¤ßŦ¹B§@¾÷±ñ²{¶H¤§«e¥²¦³¹q®ð²{¶H¡C¤U¦C¤ß©Ð¾÷±ñ²{¶H«e¥²¦³ p ªi ¡A¦]¦¹¤£§@¤ß¹q¹Ï¥i±À´ú p ªi¤§¦s¦b¡C¦óªÌ°£¥~?1. ¤ºÀVÀR¯ßaªi2. ¤ß¶W­µªi¤WÆ[¹î¨ìEªi3. ²Ä¤T¤ß­µ4. ²Ä¥|¤ß­µ
A.3
B.2 + 3
C.1 + 4
D.1 + 2 + 4
E.2 + 4
 


< ¤E¤Q¤C¦~«×¸ÕÃD¥Ø¿ý >